Skip to content
    RDNT
    Earnings call· Jun 2026(Q2 FY26)

    RadNet Q2 FY26 earnings call RDNT

    Aug 10, 2026 Source

    Executive summary

    RadNet Q2 FY26 — Record Revenue and Adjusted EBITDA Driven by Advanced Imaging and Digital Health Growth

    RadNet delivered record Q2 FY26 financial results, driven by strong advanced imaging volumes and expanding digital health solutions. The company is strategically investing in AI-powered tools and capacity expansion to address industry staffing shortages and enhance efficiency, positioning itself for continued growth and market leadership despite ongoing labor cost pressures. Management provided updated full-year guidance, reflecting confidence in its core imaging and digital health segments.

    Highlights

    5
    • Total company revenue increased 25% to $622.7 million, a quarterly record.

    • Total company adjusted EBITDA increased 22.7% to $99.7 million, a quarterly record.

    • Same-center advanced imaging procedural volumes increased 9.6% year-over-year.

    • Imaging center segment adjusted EBITDA margin improved by 17 basis points to 16.1%.

    • Digital Health Annual Recurring Revenue (ARR) reached $105.5 million, up 97% year-over-year.

    Concerns

    3
    • Digital Health adjusted EBITDA was down to $2.5 million from $3.4 million year-over-year, reflecting deliberate investments to fuel growth and acquisition dilution.

    • Continued pressure on salaries from labor shortages, particularly for technologists and radiologists.

    • Cash interest expense guidance increased by $3 million to a range of $48 million to $53 million due to incremental borrowings.

    Guidance & targets

    15
    CategoryTargetConfidence
    Digital Health Annual Recurring Revenue (ARR)
    over $140 million
    medium materiality
    High
    Digital Health Revenue
    $135 million to $145 million
    medium materiality
    High
    Digital Health Adjusted EBITDA
    $10 million to $12 million
    medium materiality
    High
    Imaging Center Segment Total Net Revenue
    $2.370 billion to $2.421 billion
    high materiality
    High
    Imaging Center Segment Adjusted EBITDA
    $345 million to $358 million
    high materiality
    High
    Free Cash Flow
    $115 million to $125 million
    high materiality
    High
    Capital Expenditures
    $165 million to $175 million
    medium materiality
    High
    Cash Interest Expense
    $48 million to $53 million
    medium materiality
    High
    Medicare Reimbursement Impact
    negative impact of less than $1 million
    medium materiality
    Medium
    RadNet Volumes through AI-powered Draft Solutions
    close to 15%
    medium materiality
    High
    RadNet Volumes through AI-powered Draft Solutions
    over 50%
    high materiality
    High
    Diagnostic Suite Reporting Pro Deployment
    full deployment
    medium materiality
    High
    Smart Registration Tool Scaling
    ready to skill
    low materiality
    High
    Glimmer Cost Synergies
    roughly $4 million
    medium materiality
    High
    Imaging Center Margin Enhancement
    100 to 150 basis point
    high materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Imaging Center Operating Segment
    Growth driven by strong increases in aggregate and same-center procedural volumes, particularly in advanced imaging, and a favorable mix shift. Operational focus on cost control contributed to margin improvement.
    Adjusted EBITDA margin: 16.1% (up 17 bps)Aggregate advanced imaging procedural volumes: increased 21.2%Same-center advanced imaging procedural volumes: increased 9.6%Aggregate MRI volume: increased 21%Same-center MRI volumes: increased 10%Aggregate CT volume: increased 20.9%Same-center CT volume: increased 8.6%Aggregate PET-CT volume: increased 31.0%Same-center PET-CT volume: increased 8.8%Advanced imaging procedural volume mix: 29.9% (up 238 bps from 27.5%)Centers in health system partnerships: 157 of 442 centers (36%)PET-CT volume from prostate PSMA and brain amyloid studies: over 25%
    16.1%
    Digital Health Operating Segment
    Strong growth driven by increased sales and licenses of enterprise imaging and AI solutions, with significant contributions from recent acquisitions. Adjusted EBITDA was lower year-over-year due to deliberate investments in growth and temporary margin dilution from acquisitions.
    Adjusted EBITDA: $2.5 million (Q2 FY26)AI revenue: $16.1 million (up 136% YoY)Enterprise imaging revenue: $16.3 million (up 17.3% YoY)Annual Recurring Revenue (ARR): $105.5 million (up 97% YoY, up nearly 9% QoQ)External ARR: 63% of ARR baseTotal contract value (TCV) closed in Q2: $21 millionTotal contract value (TCV) closed H1: $37 millionCommercial funnel TCV: more than $224 million (equivalent to $65 million ACV)Customer base: nearly 3,000 accountsTotal procedure volume across AI/informatics solutions: over $17 million (up 200% YoY)Legacy Gleaner portfolio ARR: approximately $25 million (exited Q2)EPCD program revenue: increased 16%Prostate and neuro products revenue: grew over 13%Tech Live revenue: increased over 38%Enterprise imaging workflow revenue: increased 17.3%
    $32.4 million56.5%$2.5 million

    Operational metrics

    13
    Cash balance
    $726.3 million
    Q2 FY26

    Ended the quarter with a strong cash balance.

    Revolving credit facility availability
    $282 million
    Q2 FY26

    Full availability of the revolving credit facility.

    Days sales outstanding (DSOs)
    31 daysnear RadNet low
    Q2 FY26

    Maintained DSOs at a near RadNet low, reflecting improvements in revenue cycle and patient collections.

    Total debt (par value less cash)
    $616.4 million
    Q2 FY26

    Unadjusted for bond and term loan discounts.

    New centers built
    13
    FY26 YTD

    Number of de novo centers built this year, with a similar amount expected next year.

    Ultrasound exams covered by FDA-cleared draft reporting solutions
    40%
    ongoing

    Combined coverage from breast and thyroid ultrasound AI.

    Thyroid ultrasound automated draft reports acceptance rate
    Over 90%
    ongoing

    Percentage of automated draft reports accepted by radiologists without further markups or changes.

    Breast ultrasound AI accuracy (lesion localization)
    greater than 98%
    clinical validation

    Demonstrated in validation studies for the DeepHealth breast ultrasound AI.

    Breast cancer detection sensitivity improvement (with AI)
    8%
    clinical validation

    Demonstrated in validation studies for the DeepHealth breast ultrasound AI.

    Radiologist interpretation time reduction (breast ultrasound AI)
    37%
    clinical validation

    Demonstrated in validation studies for the DeepHealth breast ultrasound AI, alongside a more standardized workflow.

    Glimmer cost synergies
    $4 million
    FY27

    Expected cost synergies from the Glimmer acquisition.

    Digital Health adjusted EBITDA margin target
    20% plusunchanged from Investor Day
    long-term

    Long-term target for the Digital Health segment's profitability.

    Digital Health core business EBITDA margins
    30% to 40%
    ongoing

    Favorable margins seen in the organic part of the Digital Health business, in line with SaaS industry expectations.

    Industry KPIs

    3
    MetricValueDetails
    Utilization trends21.2%%
    Segment revenue operating income16.1%%
    Adjusted EPS EBITDA leverage guidance99.7 millionUSD

    Product announcements

    1
    ProductTypeDetails
    DeepHealth breast ultrasound AIlaunch

    Deals & partnerships

    6
    Trinity Health St. Alfonso's health systemMulti-site joint venture for outpatient imaging centers

    Initially includes the operation of 5 multi-modality outpatient imaging centers in Boise, Idaho. The partnership will adopt various DeepHealth solutions, including diagnostic suite reporting Pro, AI studio, and clinical AI applications.

    GlimmerAcquisition of a digital health company

    Acquisition is fully integrated and performing well, with its profitability trajectory moving from negative to profitable. Organizational integration is complete, product roadmaps merged, and teams are cross-trained and cross-selling.

    CEMARAcquisition of a digital health company

    Acquisition is fully integrated and performing well, with its profitability trajectory moving from negative to profitable.

    iCADAcquisition of a digital health company

    Acquisition is fully integrated and performing well, with its profitability trajectory moving from negative to profitable.

    Southwest Florida imaging centersAcquisition of 13 imaging centers

    Part of Q1 initiatives, these centers are being transitioned onto RadNet platforms. Expected to drive additional revenue and greater operational efficiency.

    Indiana imaging centersAcquisition of imaging centers

    Acquisition mentioned as part of capital deployment, contributing to the need for credit expansion.

    Risks & headwinds

    4
    Labor shortages and salary pressureongoing

    continued pressure on salaries

    Mitigation: Implementing digital health solutions and AI tools to improve efficiency and reduce reliance on manual labor; improving recruiting and retention.

    Digital Health profitability dilutionQ2 FY26

    Adjusted EBITDA down from $3.4 million to $2.5 million YoY

    Mitigation: Deliberate investments to fuel growth, integration of acquisitions to achieve profitability, and scaling the business to leverage investments.

    Medicare reimbursement changesFY27

    negative impact of less than $1 million to 2027 revenue (initial analysis)

    Mitigation: Proposed increases to RVUs are largely mitigating the 1.68% decline in the conversion factor. Monitoring final rule release in November.

    Hospital financial pressure from site neutrality2027 (if finalized)

    significant decline in reimbursement for hospitals, anywhere between 30% and 50% decrease on these Medicare procedures

    Mitigation: Expected to drive more health system partnership discussions, as hospitals seek to offload outpatient imaging to more cost-effective providers like RadNet.

    What to watch in Q3 FY26

    5

    Digital Health ARR

    by year-end 2026
    Current$105.5 million
    Targetover $140 million

    Why it matters

    This metric indicates the growth and health of the recurring revenue component of the Digital Health segment, a key strategic growth driver for RadNet.

    We remain on track to grow full year ARR by approximately 91% from 2025 to over $140 million by the end of this year, end of 2026, with our recent acquisitions now layered on top of a healthy core business.

    Q&A highlights

    6

    What is the flow-through impact of the breast ultrasound FDA approval on the business, what is the timeline for other pending approvals, and how will reimbursement for these T codes evolve?

    Sham Sokka explained that the breast ultrasound AI will impact 1 million exams annually, 4x the volume of thyroid, reducing slot times and speeding reporting. It's eligible for an existing CPT code, and they expect to reach the 30-40% reimbursement level faster than with thyroid. Other applications in progress include image-based risk on mammography, MR Spine autografting, next-gen X-ray, CT lung AI, and vascular ultrasound.

    we will get to that reimbursement level faster with breast than we would -- than we had with thyroid.

    asked by Brian Tanquilut · answered by Sham Sokka

    2 min read6 chapters

    Detailed Narrative

    01

    Advanced Imaging Growth and Capacity Expansion

    RadNet experienced strong demand in advanced imaging modalities, including MRI, CT, and PET-CT. Aggregate procedural volumes for advanced imaging increased 21.2% year-over-year, with same-center volumes up 9.6%. This growth was attributed to broader industry trends, capital investments in faster MRI scanners, extended operating hours, and the use of Tech Live remote technologists. The favorable mix shift towards advanced imaging contributed to a 17 basis point improvement in the imaging center segment's adjusted EBITDA margin, reaching 16.1%.

    02

    Digital Health Segment Performance and AI Innovation

    The Digital Health segment reported revenue of $32.4 million, a 56.5% increase year-over-year, driven by AI and enterprise imaging solutions. Annual Recurring Revenue (ARR) grew 97% year-over-year to $105.5 million, with external ARR now accounting for 63% of the base. The company secured FDA 510(k) clearance for its DeepHealth breast ultrasound AI, which automates lesion detection and reporting, demonstrating greater than 98% accuracy and an 8% improvement in breast cancer detection sensitivity.

    03

    AI-Powered Workflow Transformation and Productivity

    RadNet is leveraging AI to transform radiology workflows, aiming for significant productivity gains. The DeepHealth breast ultrasound AI, combined with existing thyroid ultrasound AI, is expected to cover 40% of RadNet's 3 million annual ultrasound exams with potentially reimbursable draft reporting solutions. The company projects that close to 15% of RadNet's total volumes will utilize AI-powered draft solutions by year-end 2026, increasing to over 50% by the end of Q2 2027, leading to reduced interpretation times and increased capacity.

    04

    Expanding Health System Partnerships

    Joint venture relationships with health systems continue to grow, with 157 of RadNet's 442 centers (approximately 36%) now operating within these partnerships. A new multi-site joint venture was announced in Boise, Idaho, with Trinity Health St. Alfonso's, which will integrate DeepHealth solutions. Management noted increasing interest from health systems in partnering with outpatient providers and adopting digital health tools to address staffing shortages and manage imaging volumes more effectively.

    05

    Medicare Reimbursement and Site Neutrality Impact

    Initial analysis of proposed 2027 Medicare reimbursement rates suggests a near-neutral impact on RadNet's revenue, with a negative impact of less than $1 million, as proposed increases to RVUs largely mitigate a 1.68% decrease in the conversion factor. However, a proposed site neutrality provision in the HOPS Medicare fee schedule, which would significantly reduce hospital reimbursement for certain noncontrast studies (30-50% decrease), is expected to intensify financial pressure on hospital radiology departments and drive further interest in outpatient partnerships.

    06

    Strategic Acquisitions and Capital Allocation

    RadNet completed the integration of recent acquisitions, including Glimmer, CEMAR, and iCAD, which are now performing well and moving towards profitability. The company also acquired 13 new imaging centers in Southwest Florida and additional centers in Indiana. To support future growth and M&A, RadNet repriced its credit agreement, reducing interest rates by 25 basis points, and funded a $250 million incremental term loan, increasing its cash balance to $726.3 million and maintaining a net debt to adjusted EBITDA ratio of 1.8x.

    AI-generated summary of the company’s earnings call. Not investment advice.